Psychedelics: New Frontiers in Alternative Medicine
|
vol. 5 no. 5 cannabissciencetech.com
18
feature / processing/manufacturing
Mass Production
Our objective is to develop a pro-
duction facility model that can work
across borders and in low, medium,
and high output settings. We want to
model facilities that are neither space
nor power intensive. Our additional
goal is to utilize and provide effective,
commonly available equipment that
can be sourced anywhere in the world
new, used, or on a leased-basis. This
supports our goal of model portability
and product affordability.
Marketing and
Communications
Too often, marketing and communi-
cations is an afterthought in psyche-
delics. That's a mistake we will not
make. We are actively involved in
creating product narratives that will
resonate well in the earned, owned,
and paid media spaces.
Conclusion
In summary, we believe we have
outlined a sophisticated, efficacious,
yet highly portable model that can be
transferred across states and country
borders. Given adherence to this model
the goal of producing convenient, accu-
rately dosed, highly bioavailable, safe,
good tasting, and affordable psilocybin
is achievable. We are excited about the
prospect of building this valuable and
important market with high standards,
sound thinking, and care.
References
(1) https://news.yale.edu/2021/07/05/
psychedelic-spurs-growth-neural-
connections-lost-depression.
(2) https://www.hopkinsmedicine.org/psychiatry/
research/psychedelics-research.html.
(3) https://news.harvard.edu/gazette/
story/2021/06/harvard-medical-school-
professor-discusses-future-of-psychedelics/.
(4) https://dellmed.utexas.edu/news/dell-med-
launches-center-to-study-psychedelics-for-
treatment-of-depression-anxiety-ptsd.
(5) https://med.nyu.edu/departments-institutes/
population-health/divisions-sections-
centers/medical-ethics/education/
high-school-bioethics-project/learning-
scenarios/ptsd-treatment-psychedelics.
about the author
DEAN HARRIS is the CEO of TabBrands.
Direct correspondence to:
dean@tabbrands.com
CONTINUED FROM PAGE 14
holistic research done on schizophre-
nia to reframe and redefine the so-
called disease in context of western
versus traditional views and how
schizophrenia relates to psychedelics.
I wish to see the documented use and
efficacy of ayuasca in schizophrenia.
Lastly, I would like to see addition-
al research and publication of more
scientific data of African psychedelic
iboga in treatment of substance abuse
disorders.
Q:
Is there anything else you'd
like to add?
A:
Woodman: For psychedelic
therapy to be a success and
"re-integrate" its way into medicine and
society, more focus needs to be given to
finding cost efficient ways of manufac-
turing psychedelic therapies to provide
equal affordable access to all. Psyche-
delic use among African people,
including for mental health, needs to be
destigmatized globally through
awareness and education. More empha-
sis needs to be placed on set and
setting, and on setting up global
training centers for specialists who
wish to administer psychedelic
therapies. Pharmaceutical organiza-
tions will need to collaborate closely
with government institutions, regulato-
ry authorities, research organizations,
leading experts, and universities to
ensure that the education, incorpora-
tion, ethical use, and accessibility of
psychedelic medicines into a country
will benefit its people in both private
and public setting and that the
necessary infrastructures are in place to
support both patients and healthcare
providers alike.
References
(1) https://www.newswire.com/news/
cannsun-receives-approval-for-the-first-
womens-focused-phase-ii-21683642.
(2) https://journals.sagepub.com/doi/fu
ll/10.1177/00812463211001543.
(3) https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC4966661/.
(4) https://pubmed.ncbi.nlm.nih.gov/35166158/.
